http://seekingalpha.com/article/1658462-sa-pro-top-long-and-short-ideas-tuesday-august-27?source=yahoo
ZERO DEBT
CURRENT RATIO: 15.30
LOW FLOAT OF 22 MILLION
http://finance.yahoo.com/q/ks?s=LRAD+Key+Statistics
Conclusion
"With improving business prospects, a high probability of and exceptional 4Q, insider buying, and a coming buyback, we think shares of LRAD offer an asymmetric risk/reward profile. If the company indeed earns 4Q EPS of $0.05, then the company would be trading at approximately 4.5x run-rate EPS, backing out cash. If shares don't rise with the buyback, the company will be well-positioned for additional accretive share repurchases. More likely, the company will enjoy additional business wins in the months ahead, and investors will see shares rapidly move to higher levels."
"There are 5 key points that significantly bolster LRAD's bull case:
It is implicit from LRAD SEC filings that management believes the company can consistently generate at least $0.15 in annual EPS.
Based on announced wins, 4Q (September) revenue and EPS should be at least $6 million and $0.05, respectively.
There is a $3 million buyback (approximately 7% of shares at current prices) that has yet to begin, but is set to start imminently, which is likely to be executed quickly and put significant upward pressure on shares.
Two new members of the Board of Directors made open market stock purchases at higher prices since earnings.
LRAD represents a bite-size acquisition for a larger player, with LRAD offering potential for cost take-outs, a cash rich balance sheet (approximately $0.50 a share), and NOLs (NPV approximately $0.25 per share)".
http://seekingalpha.com/article/1656022-lrad-offers-catalysts-and-asymmetric-risk-reward?source=yahoo
http://seekingalpha.com/article/1649052-activist-investor-influence-at-lrad-corporation-is-creating-positive-change?source=yahoo
INSIDER BUYS this month:
Aug 12, 2013 WEND DENNIS JAMESDirector 25,000 Direct Purchase at $1.47 per share. $36,750
Aug 8, 2013 OSGOOD RICHARD HOE IIIDirector 50,000 Direct Purchase at $1.48 - $1.5 per share. $75,000
Rayank
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM